Xiaoyan Tang has extensive work experience in the life sciences field. Xiaoyan is currently serving as the Chief Investment Research Officer at Life Science Angels since August 2022. Prior to this role, they worked as an Investment Fellow specializing in biotech/genomics at the same company from April 2021 to October 2022.
Before joining Life Science Angels, Tang worked at Gladstone Institutes from 2012 to 2021. Xiaoyan'sroles at Gladstone Institutes varied over the years, starting as a Staff Research Associate I from August 2012 to April 2014. Xiaoyan then progressed to Staff Research Associate II from May 2014 to March 2016 and subsequently served as a Staff Research Associate III from April 2016 to January 2019. Tang's experience at Gladstone Institutes also includes being a Senior Research Associate from February 2019 to September 2020 and a Postdoctoral Researcher from October 2020 to March 2021.
Overall, Tang's career has spanned from research positions to their current role as Chief Investment Research Officer, demonstrating their expertise in both scientific research and investment in the life sciences industry.
Xiaoyan Tang holds a Master of Business Administration (MBA) degree from the University of California, Berkeley, Haas School of Business, specializing in Executive MBA. Prior to that, Xiaoyan obtained a Bachelor of Arts (BA) degree in Integrative Biology from the University of California, Berkeley. Additionally, Xiaoyan has earned several certifications, including a Certificate for the 2021 Inclusive Leadership Institute Program from Pneumos, an edX Verified Certificate for The Foundations of Happiness at Work from edX, and a Certificate for the "Behavioral Science of Management" - Global Network for Advanced Management, EMBA Global Network Week from Yale School of Management.
August, 2022 - present
April, 2021
Chief Scientific Officer at Biomemory
SVP for Research at Penn State University
Chief Behavioral Science Officer And President Americas at Mind Gym
Chief Research & Development Officer at Fate Therapeutics
President & Chief Science Officer at NULASTIN
Access the worlds's biggest network of public org charts
Learn more